Drug Class
BTK inhibitor
Type
ingredient
Active Ingredient
zanubrutinib
📋Overview
Zanubrutinib is a targeted therapy drug classified as a Bruton’s tyrosine kinase (BTK) inhibitor. It is primarily associated with the treatment of certain blood cancers, such as mantle cell lymphoma and chronic lymphocytic leukemia. By interfering with specific signaling pathways in cancer cells, zanubrutinib helps to slow their growth and survival. Its use is generally focused on hematologic malignancies where BTK plays a key role in disease progression.
📚References
Information from MedlinePlus.gov (NIH).
Found an Error?
Help us keep this information accurate. If you notice any incorrect details, please submit a correction request.
Find Discounts for Zanubrutinib
Hospitals.net Disclosure
Hospitals.net is an independent healthcare information platform and does not provide, administer, or guarantee prescription discounts, pricing, coupons, or pharmacy participation. All discount pricing and availability shown above are provided by RxGo and its partners and are subject to change without notice.
Hospitals.net may receive a commission or referral fee if you choose to use this prescription discount service. This does not affect the price you pay at the pharmacy. Hospitals.net is not responsible for pricing accuracy, pharmacy participation, or the fulfillment of any discount offers.